Annual Accounts Payable
$8.13 M
+$3.38 M+71.01%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual accounts payable is $8.13 million, with the most recent change of +$3.38 million (+71.01%) on December 31, 2023.
- During the last 3 years, ADAP annual accounts payable has risen by +$1.74 million (+27.22%).
- ADAP annual accounts payable is now -28.39% below its all-time high of $11.35 million, reached on December 31, 2016.
Performance
ADAP Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$9.07 M
+$1.56 M+20.71%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly accounts payable is $9.07 million, with the most recent change of +$1.56 million (+20.71%) on September 30, 2024.
- Over the past year, ADAP quarterly accounts payable has increased by +$2.48 million (+37.68%).
- ADAP quarterly accounts payable is now -80.22% below its all-time high of $45.85 million, reached on December 31, 2014.
Performance
ADAP Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ADAP Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +71.0% | +37.7% |
| 3 y3 years | +27.2% | +89.6% |
| 5 y5 years | +99.1% | +63.9% |
ADAP Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +71.0% | -43.3% | +90.8% |
| 5 y | 5-year | at high | +71.0% | -43.3% | +125.0% |
| alltime | all time | -28.4% | +1361.9% | -80.2% | +796.4% |
Adaptimmune Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $9.07 M(+20.7%) |
| Jun 2024 | - | $7.51 M(+14.1%) |
| Mar 2024 | - | $6.59 M(-19.0%) |
| Dec 2023 | $8.13 M(+71.0%) | $8.13 M(-41.6%) |
| Sep 2023 | - | $13.92 M(-5.4%) |
| Jun 2023 | - | $14.71 M(+183.7%) |
| Mar 2023 | - | $5.19 M(+9.1%) |
| Dec 2022 | $4.75 M(-41.4%) | $4.75 M(-31.2%) |
| Sep 2022 | - | $6.91 M(-56.8%) |
| Jun 2022 | - | $15.99 M(+127.9%) |
| Mar 2022 | - | $7.02 M(-13.5%) |
| Dec 2021 | $8.11 M(+27.0%) | $8.11 M(+69.6%) |
| Sep 2021 | - | $4.78 M(-31.4%) |
| Jun 2021 | - | $6.98 M(+69.5%) |
| Mar 2021 | - | $4.12 M(-35.6%) |
| Dec 2020 | $6.39 M(+0.5%) | $6.39 M(+58.5%) |
| Sep 2020 | - | $4.03 M(-54.0%) |
| Jun 2020 | - | $8.77 M(+24.1%) |
| Mar 2020 | - | $7.07 M(+11.2%) |
| Dec 2019 | $6.36 M | $6.36 M(+14.9%) |
| Sep 2019 | - | $5.54 M(+27.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $4.34 M(-19.4%) |
| Mar 2019 | - | $5.39 M(+32.0%) |
| Dec 2018 | $4.08 M(-51.3%) | $4.08 M(+4.5%) |
| Sep 2018 | - | $3.91 M(-5.4%) |
| Jun 2018 | - | $4.13 M(-18.2%) |
| Mar 2018 | - | $5.05 M(-39.7%) |
| Dec 2017 | $8.38 M(-26.2%) | $8.38 M(+236.6%) |
| Sep 2017 | - | $2.49 M(-45.6%) |
| Jun 2017 | - | $4.58 M(-11.6%) |
| Mar 2017 | - | $5.18 M(-54.4%) |
| Dec 2016 | $11.35 M(+44.0%) | $11.35 M(+255.5%) |
| Sep 2016 | - | $3.19 M(+29.1%) |
| Jun 2016 | - | $2.47 M(+1.4%) |
| Mar 2016 | - | $2.44 M(-47.7%) |
| Dec 2015 | $7.88 M(+297.8%) | - |
| Sep 2015 | - | $4.67 M(-89.8%) |
| Jun 2015 | $1.98 M(+95.9%) | - |
| Dec 2014 | - | $45.85 M(+4432.0%) |
| Jun 2014 | $1.01 M(-47.2%) | $1.01 M |
| Jun 2013 | $1.92 M(+244.5%) | - |
| Jun 2012 | $556.00 K | - |
FAQ
- What is Adaptimmune Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual accounts payable year-on-year change?
- What is Adaptimmune Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly accounts payable year-on-year change?
What is Adaptimmune Therapeutics annual accounts payable?
The current annual accounts payable of ADAP is $8.13 M
What is the all time high annual accounts payable for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual accounts payable is $11.35 M
What is Adaptimmune Therapeutics annual accounts payable year-on-year change?
Over the past year, ADAP annual accounts payable has changed by +$3.38 M (+71.01%)
What is Adaptimmune Therapeutics quarterly accounts payable?
The current quarterly accounts payable of ADAP is $9.07 M
What is the all time high quarterly accounts payable for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly accounts payable is $45.85 M
What is Adaptimmune Therapeutics quarterly accounts payable year-on-year change?
Over the past year, ADAP quarterly accounts payable has changed by +$2.48 M (+37.68%)